Press coverage about BioTelemetry (NASDAQ:BEAT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioTelemetry earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 47.3005430820752 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Investor’s Roundup (Volatility Analysis) – BioTelemetry Inc (NASDAQ: BEAT) (stockspen.com)
- Global Diagnostic Electrocardiograph (ECG) Market Growth Outlook by 2023: Suzuken, BioTelemetry, Philips and … (thefuturetechnologies.com)
- What You Must Know? BioTelemetry, Inc. (BEAT) (mostvolatilestocks.com)
- Global Electrophysiology (EP) Ablation Catheters Market 2018 – LombardMedicalTechnologiesPlc … (nwctrail.com)
- Global Cardiac Monitoring Devices Market 2018-2022: BIOTRONIK, Medtronic, ZollMedical, BioTelemetry … (cherrygrrl.com)
BEAT has been the subject of several research analyst reports. Dougherty & Co reissued a “buy” rating and set a $41.00 price objective (up previously from $40.00) on shares of BioTelemetry in a research note on Friday, February 23rd. BidaskClub raised BioTelemetry from a “hold” rating to a “buy” rating in a research note on Wednesday, February 14th. TheStreet lowered BioTelemetry from a “b-” rating to a “c” rating in a research note on Tuesday, March 20th. Finally, Zacks Investment Research raised BioTelemetry from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $43.00.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Thursday, February 22nd. The medical research company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The firm had revenue of $91.70 million during the quarter, compared to analyst estimates of $88.33 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. The company’s revenue was up 69.8% compared to the same quarter last year. research analysts expect that BioTelemetry will post 1.25 EPS for the current fiscal year.
In other news, insider Fred Broadway sold 54,158 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total value of $1,850,578.86. Following the completion of the sale, the insider now owns 64,880 shares of the company’s stock, valued at approximately $2,216,949.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 9.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact BioTelemetry (BEAT) Share Price” was originally published by BBNS and is the sole property of of BBNS. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://baseballnewssource.com/2018/03/29/biotelemetry-beat-earns-news-sentiment-score-of-0-24/1971153.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.